Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within...

Descripción completa

Detalles Bibliográficos
Autores principales: Mistry, Hema, Nduka, Chidozie, Connock, Martin, Colquitt, Jill, Mantopoulos, Theodoros, Loveman, Emma, Walewska, Renata, Mason, James
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2017
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840199/
https://www.ncbi.nlm.nih.gov/pubmed/29222670
http://dx.doi.org/10.1007/s40273-017-0599-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5840199/
https://www.ncbi.nlm.nih.gov/pubmed/29222670
http://dx.doi.org/10.1007/s40273-017-0599-9

Ejemplares similares